Medicine and Dentistry
Patient
100%
Pharmacokinetics
52%
Bleeding
47%
Blood Clotting Factor 8
46%
Von Willebrand Factor
32%
Von Willebrand Disease
32%
Bleeding Disorder
31%
Therapeutic Procedure
29%
Blood Clotting Factor 8 Concentrate
29%
Haemophilia
28%
Haemophilia A
26%
Desmopressin
22%
Person
20%
Age
17%
Woman
14%
Inpatient
13%
Hemostat
13%
Prophylaxis
12%
Joint
12%
Child
12%
Phenotype
12%
Diagnosis
12%
Diseases
11%
Body Weight
11%
Ciclonicate
10%
Assay
9%
Measurement
9%
Lochia
8%
Gene
8%
Hemarthrosis
7%
Outcome Assessment
7%
Association
6%
Analysis
6%
Sickle-Cell Disease
6%
Surgery
6%
Clearance
6%
Alloimmunization
6%
Quality of Life
6%
Fibrinogen Concentrate
6%
Weight Loss
6%
Morphometrics
6%
Obstetric Delivery
6%
Health
6%
Adult
5%
Thrombin
5%
Group Therapy
5%
Pharmacodynamics
5%
Family
5%
HLA-DRB1
5%
Substitution Therapy
5%
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacokinetics
76%
Blood Clotting Factor 8
52%
Hemophilia A
37%
Blood Clotting Factor 8 Concentrate
32%
Bleeding
21%
Hemophilia
21%
Blood Clotting Factor 9 Concentrate
15%
Pharmacokinetic Parameter
13%
Hemophilia B
10%
Blood Clotting Factor 9
9%
Base
7%
Ciclonicate
7%
Emicizumab
6%
Fibrinogen Concentrate
6%
Trough Level
6%
Thrombin
5%
Pharmacokinetic Modeling
5%
Nursing and Health Professions
Patient
29%
Blood Clotting Factor 8
26%
Bleeding
19%
Von Willebrand Factor
17%
Von Willebrand Disease
16%
Hemophilia
14%
Procedures
10%
Child
10%
Inpatient
9%
Desmopressin
9%
Ciclonicate
9%
Patient-Reported Outcome
9%
Hemophilia A
8%
Measurement
7%
Outcome Assessment
7%
Dose
7%
Perioperative
6%
Emicizumab
6%
Half Life Time
6%
Standard
6%
Bleeding Disorder
5%
Patient with Hemophilia
5%
